Stockreport

Motif Bio Confirms Meeting Date with U.S. FDA regarding Iclaprim

MOTIF BIO PLC ADRS  (MTFB) 
US:NASDAQ Investor Relations: ir.motifbio.com
PDF NEW YORK, July 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, [Read more]